Geneva, May 20 -- International Clinical Trials Registry received information related to the study (ACTRN12625000429459) titled 'A Centralized Platform study for Functional High Risk Multiple Myeloma - Master Protocol' on May 9.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Non-randomised trial
Assignment: Other
Primary Sponsor: Australasian Myeloma Research Consortium
Condition:
Myeloma
Multiple myeloma
Relapsed refractory myeloma
Myeloma
Multiple myeloma
Relapsed refractory myeloma
Cancer - Myeloma
Intervention:
Indication: All participants across all domains will have the same primary indication/inclusion criteria: Participant has functional high-risk myeloma, which is defined has having relapsed wit...